GlassScriptPhysician profile
James B Cimbak
NPI 1134270515
$1,558.26
in general payments reported to CMS, 2019-2025
10 companies · $609 in 2025
The $609 reported for 2025 was more than what 75% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
See the full distribution for Corneal and Contact Management
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $16.19 · 2021: $92.66 · 2022: $251 · 2023: $153 · 2024: $319 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,080.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $650.80 | 2021-2025 | Acuvue |
| Alcon Vision LLC | $232.61 | 2021-2025 | Precision7, Total30, Precision 1 |
| Tarsus Pharmaceuticals, INC. | $177.78 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $175.42 | 2022-2025 | Infuse, Vyzulta |
| Optovue, INC. | $118.47 | 2019 | |
| Oyster Point Pharma, INC. | $74.81 | 2022-2023 | Tyrvaya |
| Coopervision INC. | $46.57 | 2023-2024 | Myday Contact Lens, Clariti Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $31.21 | 2020-2021 | |
| Abbvie INC. | $26.00 | 2022 | |
| Sun Pharmaceutical Industries INC. | $24.59 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Cimbak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.